Correlation between androgen receptor expression and surrogate molecular subtypes in invasive breast carcinoma
10.3760/cma.j.issn.0529-5807.2017.07.006
- VernacularTitle: 雄激素受体在浸润性乳腺癌中的表达及其与乳腺癌分子分型的关系
- Author:
Xiangjie SUN
1
,
2
;
Ke ZUO
;
Shaoxian TANG
;
Hongfen LU
;
Ruohong SHUI
;
Baohua YU
;
Xiaoli XU
;
Yufan CHENG
;
Xiaoyu TU
;
Rui BI
;
Wentao YANG
Author Information
1. Department of Pathology, Fudan University Shanghai Cancer Center
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Receptors, androgen;
Molecular typing
- From:
Chinese Journal of Pathology
2017;46(7):476-480
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate androgen receptor(AR)expression in invasive breast carcinoma and the correlation with surrogate molecular breast carcinoma subtypes.
Methods:Immunohistochemical staining of AR and other biomarkers was performed in a cohort of 870 cases of primary invasive breast carcinomas collected from August to December, 2016. The association of AR expression with different histological and surrogate molecular subtypes was analyzed.
Results:The positive expression rate of AR in the immunohistochemistry-based surrogate subtypes was 96.3%(207/215) for Luminal A, 89.8%(378/421) for Luminal B, 82.4%(75/91) for HER2 overexpression and 37.1%(53/143) for triple negative breast carcinoma, with significant differences among the four groups (P<0.01). AR correlated positively with the expression of ER(P<0.01), PR(P<0.01), HER2(P=0.007), GATA3(P<0.01), GCDFP15(P<0.01)and mammaglobin(P<0.01), while negatively with the expression of Ki-67(P<0.01), CK5/6(P<0.01)and CK14(P<0.01).
Conclusions:AR exhibits a high expression in invasive breast carcinoma, which is mainly correlated with ER-positive breast carcinoma. Regardless of the relatively low expression rate, AR is a potential therapeutic target in triple negative breast carcinoma.
